REDUCTION IN MORTALITY & MORBIDITY IN HEMODIALYSIS

美国终末期肾病患者的总死亡率 通过血液透析(HD)治疗的疾病(ESRD)在过去有所增加 十年。尽管这项技术取得了许多进步，但这种情况还是发生了 与高清相关，与其他行业的趋势相比并不理想 发达国家。这个项目的目标是进行一项初步研究 这将决定实施更大规模的 多中心、前瞻性、随机试验，以评估阿司匹林的疗效 不同的血液透析技术对发病率和死亡率的影响。至少 50名慢性血液透析患者共患疾病分层，每组3人 中心将被随机纳入2(4)因子研究，以检查 透析方式(高效率与高通量)、膜的影响 类型(纤维素与聚砜)和透析处方(KT/V 0.851.0 VS 1.2-1.4)在3或4小时内交付。因为肯定 与患者相关的因素，如年龄、性别、营养状况、血液 血压(BP)、糖尿病的存在和HD的情况 Access，可以与待测试的治疗相关变量进行交互 这项研究是一项高质量医疗保健计划，将在 所有参赛者的入场方式统一。这一试点的主要成果 研究是对进行更大规模可行性的确定 通过学习，通过考核实现招聘、留住的能力 和受试者的遵从性；以及评估 因医疗原因停药等临床事件的发生 或由于实验方案的不利影响。

The gross mortality of patients in the United States with end-stage renal disease (ESRD) treated by hemodialysis (HD) has increased over the past decade. This has occurred despite numerous advances in the technology associated with HD, and compares unfavorably with trends in other developed nations. The goal of this project is to conduct a Pilot Study which will determine the feasibility of implementing a larger multi-center, prospective, randomized trial to assess the effects of different hemodialysis techniques upon morbidity and mortality. At least 50 chronic HD patients stratified for comorbid illnesses from each of 3 centers will be randomized into a 2 (4) factorial study examining the effects of dialysis modality (high efficiency vs high flux), membrane type (cellulosic vs polysulfone) and dialysis prescription (KT/V 0.851.0 vs 1.2-1.4) delivered over 3 or 4 hours time. Because certain patient-related factors such as age, gender, nutritional status, blood pressure (BP) , presence of diabetes mellitus and condition of the HD access, can interact with the treatment-related variables to be tested in the study, a program of high quality medical care will be undertaken in a uniform manner for all subjects entered. The major outcome of this Pilot Study is the determination of the feasibility of conducting a larger study, by the assessment of the ability to achieve recruitment, retention and compliance of subjects; and the assessment of the frequency of the occurrence of clinical events such as the withdrawal for medical reasons or due to adverse effects of the experimental protocols.